The Clinical Course of Treated Hyperparathyroidism Among Patients Receiving Hemodialysis and the Effect of Cinacalcet: The EVOLVE Trial-Reference-Cited by-同舟云学术

The Clinical Course of Treated Hyperparathyroidism Among Patients Receiving Hemodialysis and the Effect of Cinacalcet: The EVOLVE Trial

Published:2013-12-01 Issue:12 Volume:98 Page:4834-4844
ISSN:0021-972X
Container-title:The Journal of Clinical Endocrinology & Metabolism
language:en
Short-container-title:

Author:

Parfrey Patrick S.¹,Chertow Glenn M.²,Block Geoffrey A.³,Correa-Rotter Ricardo⁴,Drüeke Tilman B.⁵,Floege Jürgen⁶,Herzog Charles A.⁷,London Gerard M.⁸,Mahaffey Kenneth W.⁹,Moe Sharon M.¹⁰,Wheeler David C.¹¹,Dehmel Bastian¹²,Trotman Marie-Louise¹²,Modafferi Dennis M.¹²,Goodman William G.¹²

Affiliation:

1. Health Sciences Center (P.S.P.), St. John's, Newfoundland, Canada A1B 3V6

2. Stanford University School of Medicine (G.M.C.), Palo Alto, California 94304

3. Denver Nephrology (G.A.B.), Denver, Colorado 20230

4. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (R.C.-R.), Mexico City, Mexico D.F. 140100

5. Inserm Unit 1088, UFR Médecine/Pharmacie (T.B.D.), Université de Picardie, 80037 Amiens, France

6. Universitätsklinikum der RWTH Aachen (J.F.), 52074 Aachen, Germany

7. University of Minnesota (C.A.H.), Minneapolis, Minnesota 55415

8. Hôpital Manhès (G.M.L.), Paris, France 91712

9. Duke Clinical Research Institute (K.W.M.), Duke University Medical Center, Durham, North Carolina 27705

10. Indiana University School of Medicine and Roudebush Veterans Administration Medical Center (S.M.M.), Indianapolis, Indiana 46202

11. University College London (D.C.W.), London, United Kingdom NW32PF

12. Amgen, Inc (B.D., M.-L.T., D.M.M., W.G.G.), Thousand Oaks, California 91320

Publisher

The Endocrine Society

Subject

Biochemistry, medical,Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Link

http://academic.oup.com/jcem/article-pdf/98/12/4834/11128131/jcem4834.pdf

Reference21 articles.

1. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO);Moe;Kidney Int,2006

2. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients;Kalantar-Zadeh;Kidney Int,2006

3. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study;Young;Kidney Int,2005

4. Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients: the Japan dialysis outcomes and practice patterns study;Kimata;Hemodial Int,2007

5. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis;Block;J Am Soc Nephrol,2004

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Récepteur sensible au calcium (CaSR) et troubles minéraux et osseux de la maladie rénale chronique (TMO-MRC) : cibler seulement le CaSR parathyroïdien, est-ce suffisant ?;Bulletin de l'Académie Nationale de Médecine;2023-08

2. Chronic dialysis patient with severe secondary hyperparathyroidism undergoing parathyroidectomy in Indonesia: a case series;Bali Medical Journal;2023-07-10

3. Factors Associated With Persistent Post-transplant Hyperparathyroidism After Index Renal Transplantation;Journal of Surgical Research;2023-05

4. Disorders of Bone Mineral Metabolism in Chronic Kidney Disease;Pediatric Kidney Disease;2023

5. Prevention and Treatment of Bone Disease in Pediatric Dialysis Patients;Handbook of Dialysis Therapy;2023